Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease.

The recently developed ultrasensitive bio-barcode assay was used to measure the concentration of amyloid-beta-derived diffusible ligands (ADDLs), a potential soluble pathogenic Alzheimer's disease (AD) marker, in the cerebrospinal fluid (CSF) of 30 individuals. ADDL concentrations for the subjects diagnosed with AD were consistently higher than the levels in the CSF taken from nondemented age-matched controls. Studies of ADDLs or for any other potential pathogenic AD markers in CSF have not been possible because of their low concentration in CSF (<1 pM). This study is a step toward a diagnostic tool, based on soluble pathogenic markers for the debilitating disease.

[1]  J. Trojanowski.  The Molecular and Genetic Basis of Neurological Disease , 1993 .

[2]  D. Galasko,et al.  Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease , 1997, Neurology.

[3]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[4]  R. Rosenberg.  The Molecular and Genetic Basis of Neurological Disease , 1997 .

[5]  H. Braak,et al.  Evolution of neuronal changes in the course of Alzheimer's disease. , 1998, Journal of neural transmission. Supplementum.

[6]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[7]  C. Mirkin,et al.  Scanometric DNA array detection with nanoparticle probes. , 2000, Science.

[8]  Mark S. Cohen,et al.  Patterns of brain activation in people at risk for Alzheimer's disease. , 2000, The New England journal of medicine.

[9]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[10]  T. Morgan,et al.  Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies , 2001, Journal of neurochemistry.

[11]  Jeffrey L. Cummings,et al.  Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[12]  J. Vente,et al.  Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid , 2002, Neurobiology of Aging.

[13]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[14]  C. Mirkin,et al.  Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins , 2003, Science.

[15]  C. Finch,et al.  Self-assembly of Aβ1-42 into globular neurotoxins , 2003 .

[16]  R. Nitsch,et al.  Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. , 2003, Archives of neurology.

[17]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[18]  C. Finch,et al.  Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[20]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[21]  George C Schatz,et al.  What controls the melting properties of DNA-linked gold nanoparticle assemblies? , 2000, Journal of the American Chemical Society.

[22]  W. P. Hall,et al.  A Localized Surface Plasmon Resonance Biosensor: First Steps toward an Assay for Alzheimer's Disease , 2004 .

[23]  T. Nägele,et al.  Molecular imaging: Bridging the gap between neuroradiology and neurohistology. , 2004, Histology and histopathology.

[24]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[25]  [Spectral analysis of EEG coherence in Alzheimer's disease]. , 2004, Revista de neurologia.

[26]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[27]  Chad A Mirkin,et al.  Bio-bar-code-based DNA detection with PCR-like sensitivity. , 2004, Journal of the American Chemical Society.

[28]  K. Blennow.  CSF biomarkers for mild cognitive impairment , 2004, Journal of internal medicine.

[29]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[30]  Lei Chang,et al.  Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer’s disease drug candidate screening , 2007, Journal of Molecular Neuroscience.